Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wesnes, K. A.
Right arrow Articles by Lane, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wesnes, K. A.
Right arrow Articles by Lane, R.
Related Collections
Right arrowRelated Article
NEUROLOGY 2005;65:1654-1656
© 2005 American Academy of Neurology
Brief Communications

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

K. A. Wesnes, PhD, I. McKeith, MD, C. Edgar, MSc, M. Emre, MD and R. Lane, MD

From Cognitive Drug Research (Dr. Wesnes and C. Edgar), Goring-on-Thames, United Kingdom; Newcastle General Hospital (Dr. McKeith), Newcastle-upon-Tyne, United Kingdom; the Istanbul Faculty of Medicine (Dr. Emre), Istanbul, Turkey; and Novartis Pharmaceuticals (Dr. Lane), East Hanover, NJ.

Address correspondence and reprint requests to Dr. Keith A. Wesnes, Cognitive Drug Research Ltd., CDR House, Gatehampton Road, Goring-on-Thames, RG8 0EN, UK; e-mail: keithw{at}cdr.org.uk

In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.

Supported by Novartis Pharma AG.

Disclosure: K.A. Wesnes, PhD, is the owner of Cognitive Drug Research Ltd., which was financially supported in excess of $10,000 for its involvement in this study. C. Edgar, MSc, is a nonequity employee of Cognitive Drug Research Ltd. I. McKeith, MD, has received honoraria from Novartis. M. Emre, MD, has received study grants (in excess of $10,000) and honoraria from Novartis. R. Lane, MD, is an employee of Novartis and owns stock options in excess of $10,000.

Received April 27, 2005. Accepted in final form August 5, 2005.


Related Article

November 22 Highlights
Neurology 2005 65: 1518-1519. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Ann Intern Med, March 4, 2008; 148(5): 379 - 397.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K Bronnick, U Ehrt, M Emre, P P De Deyn, K Wesnes, S Tekin, and D Aarsland
Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, October 1, 2006; 77(10): 1136 - 1142.
[Abstract] [Full Text] [PDF]